| SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI® (NCT05546398) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2022-04-22 |
| Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (NCT05118230) | Novartis Pharmaceuticals | 2021-12-09 |
| Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia (NCT04998201) | Arrowhead Pharmaceuticals | 2021-09-28 |
| Study of ARO-ANG3 in Adults With Mixed Dyslipidemia (NCT04832971) | Arrowhead Pharmaceuticals | 2021-06-28 |
| An Observational Study on the Identification of Prescription Patterns of STAFEN Cap (NCT06204380) | Hanlim Pharm. Co., Ltd. | 2021-04-21 |
| Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia (NCT04579367) | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2021-01-15 |
| Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia (NCT03433755) | Amgen | 2019-05-09 |
| A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe (NCT03648788) | IlDong Pharmaceutical Co Ltd | 2018-09-01 |
| Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia (NCT02739984) | Amgen | 2016-05-17 |
| Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab (NCT02275156) | Amgen | 2014-08-19 |
| Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen (NCT01879319) | Amgen | 2013-07-11 |
| Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen (NCT01849497) | Amgen | 2013-04-18 |
| Bezafibrate Plus Berberine in Mixed Dyslipidemia (NCT02548832) | University of Guadalajara | 2013-04-01 |
| Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) (NCT01335997) | Merck Sharp & Dohme LLC | 2011-05-01 |
| Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) (NCT01274559) | Merck Sharp & Dohme LLC | 2011-03-01 |
| Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119) (NCT01228019) | Merck Sharp & Dohme LLC | 2010-12-01 |
| Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia (NCT01256476) | Kowa Research Institute, Inc. | 2010-10-01 |
| Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood (NCT00639158) | Abbott | 2008-02-01 |
| Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) (NCT00479388) | Merck Sharp & Dohme LLC | 2007-07-01 |
| MK-0524B Lipid Study (MK-0524B-063) (NCT00479882) | Merck Sharp & Dohme LLC | 2007-06-15 |
| A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia (NCT00491530) | Abbott | 2007-06-01 |
| An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) (NCT00465088) | Abbott | 2007-04-01 |
| An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia (NCT00487591) | Provident Clinical Research | 2006-11-01 |
| Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. (NCT00300430) | Abbott | 2006-09-01 |
| Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood (NCT00300469) | Abbott | 2006-03-01 |
| Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood (NCT00300482) | Abbott | 2006-03-01 |
| Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood (NCT00300456) | Abbott | 2006-03-01 |
| Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia (NCT00136799) | Novartis | 2005-06-01 |
| Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study (NCT00309712) | Intermountain Health Care, Inc. | 2002-08-01 |
| Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia (NCT00171236) | Novartis | 2001-10-01 |